BERLIN (dpa-AFX) - Merck KGaA (MKGAY.PK) on Thursday said it has agreed to
acquire Mirus Bio, a life science company that develops transfection reagents,
for $600 million.

Transfection reagents such as Mirus Bio's TransIT-VirusGEN, are used to help
introduce genetic material into cells.

'Combining Mirus Bio's leading technology with Merck's bioprocessing expertise
and portfolio allows us to provide solutions for almost every step of viral
vector development and manufacturing,' said Matthias Heinzel, Member of the
Executive Board of Merck and CEO Life Science.

Merck has engaged Gamma Biosciences, a life sciences platform established by
global investment firm KKR, for the acquisition of Mirus Bio. The deal is
expected to close in the third quarter of 2024.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX